

Press release PKvitality
Paris, April 19th, 2022

PKvitality to Announce First-In-Human Clinical Results at the 15th ATTD Conference

At the forefront of diabetes innovation, PKvitality has developed K'Watch Glucose, the world's first Continuous Glucose Monitoring (CGM) smartwatch.



*K'Watch Glucose will be on display at:
Booth 36, ATTD conference, April 27 to 30, 2022, Barcelona, Spain*

A presentation will take place on April 29 at 12h30, ATTD Conference, Exhibition Area

Paris, April XXth, 2022 – PKvitality, a French company specializing in Bio-wearable Health and Sports, will disclose the first-in-human results of K'Watch Glucose, the Continuous Glucose Monitoring device in the form of a smartwatch, at the 15th annual ATTD conference in Barcelona, Spain. Glucose monitoring is incredibly challenging for Type 1 & Type 2 diabetes patients, especially in terms of precision, tolerance, and pain. Based on these criteria, the trial led by PKvitality were successful and showed great user experience and tracking. The trial took place at AMCR Institute, a clinical research center focused on diabetes and obesity with worldwide renowned medical device expertise in the metabolic area. Non-invasive, precise and affordable, K'Watch will change the everyday lives of diabetics!

PKvitality will officially attend Europe's most anticipated conference on Advanced Technologies and Treatments for Diabetes (ATTD) - from April 27-30, 2022, in Barcelona. On this occasion, the results of the First In Human Clinical Trials of K'Watch Glucose will be presented in an e-poster by Timothy Bailey, Principal Investigator of the trial and MD, FACE, CPI and CEO of AMCR Institute. These clinical results will be explained, on-site, by Minh Lê, General Manager of PKvitality.

Details of the event:

- ***ATTD, April 27 to 30: PKvitality Booth #36***

- **Presentation: Friday, April 29th from 12h30 -12h40 at the Exhibition Area**

PKvitality: the success of future glucose monitoring technologies

Pkvitality mission is to enable everyone to be actively involved in their well-being and health through pleasant and straightforward products. The company developed K'Watch Glucose, the world's first CGM (Continuous Glucose Monitor) device that will track glucose levels continuously and discreetly. The system will measure glucose levels in the clinical stage by analyzing interstitial fluid (ISF) through micropoints. The system enables a painless and non-stigmatizing experience, solving the adhesive issue in a design-to-cost architecture. Its First-In-Human clinical trials were completed with positive outcomes! Great user experience means no adverse events, no pain, no irritation to patients and a very tolerance.

At the crossroad of Medtech and Deeptech, Pkvitality has the support of Bpifrance and EIC Accelerator, is accelerated by Dassault Systemes and Future4care – the largest European Health accelerator -, and is the winner of multiple awards, including Best of CES, EIT health Catapult, and the Healthcare Innovation World Cup.

Arnaud Malet, Medical and Clinical Manager at Pkvitality, declared: *“Pkvitality has made tremendous progress in the last few months, having begun our first-in-human clinical trials at the end of 2021. The support and network we receive from ATTD are unique, as professionals worldwide come together for four days to display the most advanced and latest technologies for diabetes treatments. We are looking forward to ATTD presenting our excellent clinical results to an innovative and educated audience with the same mindset of helping improve the lives of diabetes patients, and to exchange with the experts of the industry.”*

The ATTD Conference came at an ideal time for Pkvitality. They closed their Series A funding round in early 2022 with six m€ in funding. Pkvitality has raised over 18 m€ of financing since the beginning. They will now kick off their series B funding round based on their first-ever in-human trials. They are also present on the French crowdfunding platform Wiseed, which is open to any investor (more info [here](#)).



K'Watch Glucose, the 1st smartwatch to monitor glucose

K'Watch will be the first Continuous Glucose Monitor in the form of a smartwatch. It is composed of two parts: K'Watch, the smartwatch and K'apsul, an adhesive patch at the back. It will enable a continuous monitoring of systemic glucose levels anytime and anywhere. This is possible thanks to SkinTaste®, a patented biosensor array that uses micropoints (<1mm long) in order to analyze chemical compositions of the interstitial fluid. Completely painless and invisible to others, the diabetes patient will be able to check its level discreetly or follow its average glucose and time in range.

To access the study, please click [here](#).

To access a video, please click [here](#).

About ATTD

The ATTD (Advanced Technologies and Treatments for Diabetes) Conference aims to highlight cutting-edge diabetic treatment methods. It brings together new technology developers with diabetes specialists and caregivers and familiarizes practitioners with innovative treatment strategies. International experts discuss and spread information on the most cutting-edge technology and therapies in our industry. Clinicians in diabetes, endocrinology, metabolism, pediatricians and family care practitioners, and diabetes technology innovators make up the audience. They've come from all around the world, from academic institutions to primary care clinics.

About PKvitality

PKvitality is a health & sport bio-wearable scale-up currently working on K'Watch Glucose, a Continuous Glucose Monitoring (CGM) device in the form of a smartwatch presently in clinical trials. It will enable painless, discreet and precise monitoring of systemic glucose levels anytime and anywhere. Using the same technology, PKvitality is also working on K'Watch Athlete, a smartwatch that will provide real-time tracking of their lactic acid – an indicator of muscle fatigue – to significantly improve an athlete's training and performance.

For more information, please visit www.pkvitality.com.

Press Contacts:

Jean-François Kitten - jf@licencek.com - +33(0)6 11 29 30 28

Ilinca Spita – i.spita@licencek.com - +33(0)6 64 75 12 98 (EN)

Constance Leglise – c.leglise@licencek.com +33(0)6 65 20 00 56

Investors : contact-funding@pkvitality.com

Partners/ KOLs : partnership@pkvitality.com or meet PKvitality on booth 36 at the ATTD conference.

Other contacts : contact@pkvitality.com



This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 960071.